Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes

Abstract

Cristina Saavedra,1,2 Jorge Barriuso,1,3 Mairéad G McNamara,1,3 Juan W Valle,1,3 Angela Lamarca1,31Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, UK; 2Medical Oncology Department, Ramon Y Cajal University Hospital, Madrid, Spain; 3Division of Cancer Sciences, University of Manchester, Manchester, UKAbstract: Neuroendocrine tumors (NETs) are rare cancers with an associated prolonged survival in some patients. A proportion of patients diagnosed with NETs will present with carcinoid syndrome symptoms, characterized by diarrhea, flushing and/or wheezing. This review summarizes the current treatment options for carcinoid syndrome, focusing on the latest novel treatment option, telotristat ethyl. In addition, information on patient-reported outcomes and impact of carcinoid syndrome on quality of life (QOL) and improvement of following treatment with telotristat ethyl are reviewed. This article also provides an overview of the current QOL questionnaires for patients with NETs and addresses unmet needs in this field of patient-reported outcomes.Keywords: telotristat ethyl, carcinoid syndrome, NET, diarrhea

Keywords

• telotristat ethyl
• carcinoid syndrome
• NET
• diarrhoea